Literature DB >> 20655401

Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.

Sabine Becke1, Steffi Aue, Doris Thomas, Sina Schader, Jürgen Podlech, Tobias Bopp, Tina Sedmak, Uwe Wolfrum, Bodo Plachter, Sabine Reyda.   

Abstract

Control of human cytomegalovirus (HCMV) infection correlates with the reconstitution of antiviral T lymphocytes in haematopoietic stem cell transplant recipients. A vaccine to foster this reconstitution and to ameliorate the severe consequences of HCMV reactivation is yet unavailable. This work focused on providing a rationale for the amendment of the yields and the antigenic composition of a vaccine, based on subviral dense bodies (DB) of HCMV. Modified DB were generated that contained the HLA-A2 presented IE1 model peptide TMYGGISLL, integrated at different positions in the major DB protein pp65. Insertion at position W175 of pp65 allowed efficient formation of recDB in the cytoplasm of infected cells and resulted in considerable yields of these particles. Even in the absence of adjuvant, these particles proved to be highly immunogenic with respect to CD8 and CD4 T cell and neutralizing antibody responses. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655401     DOI: 10.1016/j.vaccine.2010.07.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors:  Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 2.  Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.

Authors:  Stephan J Wu; Daniel O Villarreal; Devon J Shedlock; David B Weiner
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Authors:  Marc Kirchmeier; Anne-Catherine Fluckiger; Catalina Soare; Jasminka Bozic; Barthelemy Ontsouka; Tanvir Ahmed; Abebaw Diress; Lenore Pereira; Florian Schödel; Stanley Plotkin; Charlotte Dalba; David Klatzmann; David E Anderson
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

4.  Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.

Authors:  Caroline Lehmann; Jessica Julia Falk; Nicole Büscher; Inessa Penner; Christine Zimmermann; Patricia Gogesch; Christian Sinzger; Bodo Plachter
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 5.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

6.  The tegument protein pp65 of human cytomegalovirus acts as an optional scaffold protein that optimizes protein uploading into viral particles.

Authors:  Sabine Reyda; Stefan Tenzer; Pedro Navarro; Wolfgang Gebauer; Michael Saur; Steffi Krauter; Nicole Büscher; Bodo Plachter
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 7.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 8.  The history of vaccination against cytomegalovirus.

Authors:  Stanley Plotkin
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

9.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

10.  The Abundant Tegument Protein pUL25 of Human Cytomegalovirus Prevents Proteasomal Degradation of pUL26 and Supports Its Suppression of ISGylation.

Authors:  Christine Zimmermann; Nicole Büscher; Steffi Krauter; Nadine Krämer; Uwe Wolfrum; Elisabeth Sehn; Stefan Tenzer; Bodo Plachter
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.